drugset / Trial / NCT02648633

Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma

NCT02648633

Phase 1 Terminated 4 enrolled University of Virginia
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and feasibility of the immunotherapeutic agent nivolumab given in combination with gamma knife therapy and valproate in patients with recurrent glioblastoma, a common and lethal type of brain cancer.

Timeline

Start
2016-05-24
Primary completion
2017-02-21
Completion
2017-02-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Nivolumab Monoclonal antibody 3 mg/kg Intravenous
Subject Valproate Small molecule

Indications